Skip to main content
. 2020 Oct 23;99(43):e22785. doi: 10.1097/MD.0000000000022785

Figure 3.

Figure 3

Schematic representation of the clinical history, therapy, and visits of a patient diagnosed with nonkeratinizing undifferentiated nasopharyngeal carcinoma (stage IV, cT4, cN1, cM0) in March, 2012 (V0). After concurrent RCT (paclitaxel /nedaplatin, 73Gy), a partial tumor response was evidenced by MRI scanning (V1). Two years later (V2, 7/2014), the patient received concurrent RCT (gemcitabine/cisplatinum, 67 Gy and 66 Gy), the state of the disease recurrence was evidenced much better than before by MRI scanning (V3). Three months later (V4), MRI scanning showed no tumor progression. On March, 2016, the MRI examination of brain indicated intracranial metastases (V5). On July, 2016 (V6), the patient began to receive NK cell treatment on a 3-yearly basis. MRI scanning after NK therapy (V7–V10) revealed that the intracranial metastases was gradually shrinking or even disappearing.